Broader Medicare Coverage For Leqembi Begins As CMS-Backed Registry Opens For Business
There is no fee to participate, and entries to the registry must be made at baseline and then every six months for up to two years.
You may also be interested in...
Now that it’s clear the Centers for Medicare and Medicaid Services is moving ahead with the patient registry requirement for the Alzheimer’s drug, experts weigh in on how best to collect useful information.
After a decade of curtailed use, new drugs make wider availability important for patient selection and safety, CMS says in a new amyloid PET scan proposal.
Senior Centers for Medicare and Medicaid Services official Lee Fleisher described the game plan behind the CMS-facilitated patient registry for the new Alzheimer’s disease treatment, but former CMS official Sean Tunis is still concerned the approach won’t meet data expectations in the planned two-year window.